首例临床患者17小时从重症到恢复 瑞德西韦真是新冠肺炎神药？_腾讯新闻。
The first clinical patient 17 hours from severe to recovery Rhetsevir is the new crown pneumonia miracle drug? _ Tencent News.
// 判断如果是动态底层不加载此JS逻辑 2020/1/19。
/ / Determine if the dynamic underlying layer does not load this JS logic 2020 / 1 / 19.
"title": "首例临床患者17小时从重症到恢复 瑞德西韦真是新冠肺炎神药？",。
& quot; & quot; & quot; & quot; & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45;
"introduction": "瑞德西韦已在我国进入临床测试阶段，《潜望》从接近该临床试验人员处获悉，瑞德西韦试验的第一例患者从重症到恢复，用时不到24小时，“效果很好”。
Rhett & quot; Rhetsett & quot; Rhettiv has entered clinical trials in our country, and Deep Hope was told by people close to the clinical trial that the first case of Rhetsevier's test took less than 24 hours to recover from severe illness, "with good results."
",。
& quot; & quot;
"media": "潜望",。
AT & quot; Med & quot; & quot; & quot; & quot; & quot; & quot; & quot;
"tags": "新型冠状病毒,埃博拉病毒,特效药,瑞德西韦,潜望,gilead",。
& quot; T & quot; & quot; New coronavirus, Ebola, drugs like Rhetsevir, Stealth, gilead & quot; & quot;.
要闻娱乐财经体育图片时尚军事游戏科技数码百态房产汽车文化教育健康动漫旅游生活美食星座育儿历史政务正在阅读：首例临床患者17小时从重症到恢复 瑞德西韦真是新冠肺炎神药？一键登录 。
/ [^ # 39 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 105 ^ # 116] / n.
首例临床患者17小时从重症到恢复 瑞德西韦真是新冠肺炎神药？。
The first clinical patient 17 hours from severe to recovery Rhetsevir is really the new crown pneumonia miracle drug?
202002/0408:06潜望分享用微信扫描二维码评论1571。
202002 / 0408: 06 Prospect Sharing with Micromail Scanning 2D Comments 1571.
瑞德西韦已在我国进入临床测试阶段，《潜望》从接近该临床试验人员处获悉，瑞德西韦试验的第一例患者从重症到恢复，用时不到24小时，“效果很好”。
Rhetsevier has entered clinical trials in China, where Diving Hope was told by people close to the clinical trial that the first case of the Rhetsevier trial, which took less than 24 hours from severe to recovery, was "very effective."
。
.
《潜望》 作者 纪振宇 刘鹏。
Liu Peng, Ji Zhenyu, the writer.
一起基于“同情用药”准则下的治愈案例，让美国制药公司Gilead几年前针对埃博拉病毒而研制的药物瑞德西韦（Remdesivir），成为扼住肆虐的新型冠状病毒咽喉的新希望。
A case of a cure based on the "compassionate medication" principle has given US pharmaceutical company Gilead the drug Remdesivir, developed a few years ago in response to the Ebola virus, renewed hope of choking off the raging coronavirus.
。
.
与此几乎同时，泰国也宣布发现治疗新冠肺炎的药方，两种药物分别是抗艾滋病药物和抗流感药物（Oseltamivir），曼谷Rajavithi医院的医生团队表示，经近日的临床使用发现效果非常好，多名确诊病例服用完后，12小时内病情明显好转，48小时内痊愈。
At about the same time, Thailand announced the discovery of a cure for pneumonia, an anti-AIDS and anti-flu drug, Oseltamivir. The team of doctors at Bangkok's Rajavithi Hospital said recent clinical trials had shown positive results, with many confirmed cases apparently cured within 12 hours after treatment.
。
.
多重“好消息”之下，似乎利器已然在手，战胜新型冠状病毒迎来曙光。
Under the multiple "good news", it seems that the sharp weapon is already in hand to defeat the new coronavirus ushered in dawn.
但这些个例背后很难说清，到底是这些“特效药”起了作用，还是患者自身免疫系统战胜了病毒。
But it is hard to say behind these cases whether these "specific drugs" worked, or whether the patient's own immune system overcame the virus.
毕竟在国内，没有这些“特效药”帮助下，治愈的案例已高达400例。
At home, after all, 400 cases have been cured without the help of these "magic cures."
。
.
但不得不承认，这是新型冠状病毒疫情爆发以来，人们在朴素的战胜病毒心理下看到的希望所在。
But it has to be admitted that this is the new coronavirus outbreak, people in the simple fight against the virus see the hope.
。
.
根据临床实验注册信息，2月3日，瑞德西韦这一“特效药”随机、双盲、对照III期临床研究正式启动，总样本量270例，入组轻、中度新冠肺炎患者,由中日友好医院曹彬教授牵头，预期在4月27日结束。
Rhetsevir, a randomized, double-blind, controlled phase III clinical study with 270 cases of mild to moderate Newcomotic Pneumonia, led by Professor Cao Bin of the Sino-Japanese Friendship Hospital, was launched on February 3.
。
.
当日晚间，即有传言称，瑞德西韦试验的第一例患者从重症到恢复，用时不到24小时，“效果很好”。
Late that day, rumors spread that the first case of the Rhetsevier trial, which took less than 24 hours from critical illness to recovery, was "very effective."
不过，与美国宣布用该药物治愈的患者一样，目前均为孤例，没有对照试验，没有足够的临床样本，不能证明就是“特效药”起了作用。
However, as in the case of patients who have been declared cured by the drug in the United States, there are no controlled trials, there are not enough clinical samples to prove that "specific drugs" work.
。
.
“希望在新药审批的正规流程下，瑞德西韦能够开展正规的人体临床试验，确定在治疗治疗新型冠状病毒感染上的安全性和有效性。
"Hopefully, Rhetsevir will be able to conduct formal clinical trials in humans to determine the safety and efficacy of the new coronavirus infection in the treatment and treatment of new coronavirus infections."
”浙江大学教授王立铭在谈及瑞德西韦这一“特效药”时表示，如果证明安全好用，可以和吉利德公司一起推动这种药物的正式上市和进口，保证中国患者能够使用到。
Professor Wang Liming of Zhejiang University, referring to Rhettifov's "miracle drug," said he could work with Geely to get the drug officially on the market and imported to make it accessible to Chinese patients.
。
.
但他同时强调，瑞德西韦需要严格遵循新药开发的规律，不能随意缩短研究的时间和标准。
But he also stressed the need for Rhetsevius to strictly follow the rules of new drug development and not shorten the time and standards of research at will.
因为“不管疾病有多严重，不管我们期待新药和新疫苗的愿望是多么迫切，新药和新疫苗开发的规律无法被逾越。
For "no matter how serious the disease may be, no matter how urgent our desire for new drugs and vaccines may be, the laws governing the development of new drugs and vaccines cannot be overcome."
”。
"
治愈美国首例新冠病毒患者。
Cure the first case of New Crown Virus in America.
据《新英格兰医学杂志》报道，美国首例确诊新冠病毒病人于1月15日结束了在武汉的探亲返回美国，在返美后的第二天就开始咳嗽，并有些发热症状，第三天由于症状仍未缓解，并在了解到新冠病毒相关消息后，决定去看医生。
The New England Journal of Medicine reported that the first confirmed case of the virus returned to the United States on January 15 after visiting relatives in Wuhan, coughed the day after returning to the United States, developed fever symptoms, remained unrelieved on the third day and decided to see a doctor after learning about the virus, the New England Journal of Medicine reported.
。
.
在接受了几天的治疗后，病人的病情并未得到缓解，并有不断加重趋势，在住院后第六天，患者出现持续高烧，需要吸氧，肺部X光片显示出非典型肺炎的特征。
After several days of treatment, the patient's condition did not improve and there was an increasing trend. On the sixth day of hospitalization, the patient developed a persistent high fever requiring oxygen inhalation and X-rays of the lungs showed signs of atypical pneumonia.
最终患者使用了一种尚未获批的新药，由吉利德公司研发的抗病毒药伦地西韦。
The final patient used an unapproved new drug, Rendicavir, an antiviral drug developed by Geely.
。
.
在使用该药物后的第二天，病人的病情并得到了极大的改善，他不再需要吸氧，除了干咳和流鼻涕，他已经没有其他症状，截至1月30日，这名患者仍在住院观察，但已经退烧，目前唯一症状是咳嗽，且严重程度在不断减轻。
The day after the medication was administered, the patient's condition was greatly improved, he no longer needed oxygen, he had no symptoms other than dry cough and runny nose, and as of 30 January the patient was still hospitalized but fever had subsided and the only symptom was cough, which was becoming less severe.
。
.
值得强调的是，由于伦地西韦是未被美国药监局（FDA）批准的新药，因而用在病人身上已经属于同情用药（英文名：Compassionate use）的范畴。
It is worth emphasizing that, because Rendiche is not a new drug approved by the US Drug Administration (FDA), its use in patients is already covered by Compassionate use.
。
.
所谓同情用药，是属于治疗过程中的一种极端情况，美国药监局对其有着非常严格的界定，在其官网上，FDA明确列出，必须满足下列所有条件，才被认为同情用药是妥当的：。
Compassion is an extreme form of treatment that is very narrowly defined by the United States Drug Enforcement Administration (FDA). On its website, FDA specifies that all of the following conditions must be met in order to be considered appropriate for compassionate medication:
1、病人病情严重，或者病情已经能够立即对生命造成威胁。
1. The patient is seriously ill or is already capable of causing an immediate threat to life.
。
.
2、没有其他类似或有效的可选诊断、检测或治疗方案。
2. There are no other comparable or effective alternative diagnosis, testing or treatment options.
3、病人无法被列入临床试验。
Patients cannot be included in clinical trials.
4、（用药后）病人潜在能够收获的疗效，值得付出这样的风险。
It is worth the risk that the patient may be able to reap the benefits of the drug.
5、治疗药物不会对临床试验以及治疗效果的宣传产生影响。
5. Therapeutic drugs do not affect clinical trials and the promotion of therapeutic efficacy.
FDA还专门提醒，对于尚处于试验阶段的新药或医疗设备的使用，或许将会导致预期之外的严重的副作用。
The FDA also specifically warned that the use of new drugs or medical devices that are still in the pilot phase could lead to serious unintended side effects.
。
.
从FDA的上述规定以及再三提醒不难看出，对于未经获批的新药的使用，监管当局的态度是极其慎重，只有在极端情况，且满足各项条件时，才能将未经获批的新药用于病患身上。
From the FDA's provisions and repeated reminders, it is easy to see that regulatory authorities are extremely cautious about the use of unapproved new drugs, and that unapproved new drugs can only be used on patients in extreme circumstances and when conditions are met.
。
.
瑞德西韦与制药公司Gilead的前世今生。
Rhetsevius and Gilead, a pharmaceutical company, lived a lifetime.
用于美国首例新冠病毒患者的治疗的Remdesivir，是由美国生物制药公司Gilead 几年前针对非洲流行的埃博拉病毒所研制的抗病毒药剂，但从临床试验效果来看，实际上Remdesivir对埃博拉病毒患者的治疗效果并不好，与其他三款针对埃博拉病毒研制的药剂同时进行临床试验时，接受Remdesivir治疗的埃博拉病毒感染患者的致死率最高。
Remdesivivir, the first anti-viral agent developed by the United States biopharmaceutical company Gilead several years ago for the Ebola epidemic in Africa, actually proved ineffective in treating Ebola patients, with the highest mortality rates among Ebola virus-infected patients treated with Remdesivir in parallel with three other Ebola-developed preparations.
。
.
在2019年10月由美国国家过敏与传染病研究机构公布的一篇论文中称，总共1400多名接受临床试验的患者被随机分配四种药的治疗，分别是ZMapp、Mab114、REGN-EB3和Remdesivir，最终，接受ZMapp治疗的患者死亡率为49%，接受mAb114治疗的患者死亡率 为34%，接受REGN-EB3治疗的患者死亡率为29%，而接受Remdesivir治疗的患者死亡率最高，达到53%，埃博拉病毒爆发的总体死亡率为67%。
According to a paper published in October 2019 by the National Institute of Allergy and Infectious Diseases, a total of more than 1,400 patients undergoing clinical trials were randomly assigned four treatments: ZMapp, Mab114, REGN-EB3 and Remdesivivir, with a mortality rate of 49%, mAb114 with 29%, and Remdesivir with 53% and 67% respectively.
。
.
基于这样的临床试验结果，试验数据和安全监测委员会决定，继续进行死亡率最低的两款药REGN-EB3和mAB114的试验，而解除了另两款药ZMapp和Remdesivir的继续试验。
Based on the results of such clinical trials, the Test Data and Safety Monitoring Committee decided to continue the trials of the two drugs with the lowest mortality rates, REGN-EB3 and mAB 114, and to release the remaining two, ZMapp and Remdesivir.
。
.
研制Remdesivir的制药公司Gilead是一家总部位于美国加州Foster City的生物医药公司，从事药品的研发和商业化，主要研发包括用于治疗HIV、甲肝、乙肝和流感等病毒的抗病毒类药物。
Gilead, a pharmaceutical company that develops Remdesivir, is a pharmaceutical company based in Foster City, Calif., that specializes in the development and commercialization of drugs, including antiviral drugs for the treatment of HIV, hepatitis A, hepatitis B and influenza.
。
.
Gilead于1987年创办，1992年在纳斯达克交易所上市交易，目前市值约800亿美元，员工数超1万名。
Founded in 1987 and traded on the Nasdaq Stock Exchange in 1992, Gilead now has a market capitalisation of about $80 billion and more than 10,000 employees.
。
.
近年来，Gilead作为一家上市公司的经营业绩状况并不好，近三年销售收入连年下滑，2018年销售收入同比下滑16%至217亿美元，其中HIV相关药物销售下滑12%至146亿美元，HCV相关药物销售大幅下滑60%至37亿美元。
Sales have fallen 16% to $21.7 billion year-on-year in 2018, with HIV-related drug sales down 12% to $14.6 billion and HCV-related sales down 60% to $3.7 billion.
。
.
去年全年，Gilead股价下跌7%，而标普医药板块去年整体则上涨17%。
Gilead shares fell 7 per cent last year, compared with a 17 per cent rise in S & P Pharmaceuticals as a whole last year.
在治愈美国首例新冠病毒患者之前，Gilead的股价一度已经下滑到7年新低。
Gilead's share price had fallen to a seven-year low before the country's first case of the virus was cured.
由于美国首例新冠病毒患者接受Remdesivir的消息，使得Gilead股价在消息当天一度上涨超过7%。
Gilead's shares jumped more than 7 percent on the day of the news as the first U. S. case of the virus was reported to have accepted Remdesivivir.
。
.
将用于大规模临床试验。
Will be used in large clinical trials.
2月2日，中国国家药监局药品审评中心（CDE）正式受理瑞德西韦的临床试验申请。
On February 2, the Drug Review Center (CDE) of China's State Administration of Pharmacy officially accepted Rhetsevir's application for clinical trials.
2月3日，瑞德西韦这一“特效药”随机、双盲、对照III期临床研究正式启动，总样本量270例，入组轻、中度新冠肺炎患者,由中日友好医院曹彬教授牵头，在武汉疫区展开，预期在4月27日结束。
On February 3, Rhetsevir, a randomized, double-blind, controlled phase III clinical study, was launched, with a total sample size of 270 cases. Led by Professor Cao Bin, a Sino-Japanese friendly hospital, it is expected to end on April 27.
。
.
中日友好医院在官网表态，在武汉疫区牵头开展瑞德西韦(Remdesivir)治疗2019-nCoV新型冠状病毒临床研究，将“为抗击疫情带来曙光。
The China-Japan Friendship Hospital announced on its website that a clinical study led by Remdesivir to treat 2019-nCoV, a new coronavirus, in an epidemic-stricken region of Wuhan, will "provide hope for the fight against the epidemic.
”。
"
但结合目前所掌握的现有信息来看，至少有几方面的问题值得提出：。
On the basis of the available information, however, there are at least a few issues that deserve to be raised:
首先，Remdesivir在治愈美国患者这件事中所起到的作用还未能得到充分的论证。
First, the role of Remdesivir in curing American patients has not been fully demonstrated.
。
.
根据《新英格兰医学日志》1月31日所刊登的文章叙述，在首例新冠病毒患者入院第7天晚对其使用Remdesivir，第8天，病人的病情得到显著改善，血氧水平从94%上升至96%，但文章仅仅是客观叙述事实，并没有做出任何“是因为使用Remdesivir而使病人病情好转”的结论。
According to an article published in the New England Journal of Medicine on January 31, Remdesivivir was used on the seventh night of admission. On the eighth day, the patient's condition improved significantly, from 94% to 96%.
。
.
此外，一位熟悉该流程的美国医学教授对《潜望》指出，在介绍其诊疗过程的文章中，患者第12天鼻腔试纸病毒检测结果并未转阴，依然呈阳性，并不符合国家颁布的治愈标准。
In addition, an American medical professor familiar with the procedure told the paper that in the article describing his diagnosis and treatment, the patient's 12-day-old nasal strip virus test did not turn cloudy, remained positive and did not meet the nation's prescribed treatment standards.
。
.
（上图红框中鼻腔试纸病毒检测结果依然为阳性）。
(The results in the red box above are still positive).
在Gilead公司随后发表的声明中，该公司除了强调本药并没有获批，还处于临床试验阶段外，也表示，Remdesivir对于与新型冠状病毒结构相似的SARS和MERS病毒有一定效果外，并没有直接的对新型冠状病毒有效的数据，该公司也没有在声明中明确表示，美国首例新型冠状病毒患者状况改善是因为该药所起的效果。
In a subsequent statement, Gilead, while stressing that the drug had not been approved and was in clinical trials, said that Remdesivivir had no direct data on the coronavirus other than the new coronavirus, which has a similar structure to that of the new coronavirus.
。
.
其次，即便是有充分证据说明美国首例治愈病例确实是因为Remdesivir起作用，但别忘了该药最初是针对埃博拉病毒进行研发，现在却对新冠病毒起作用，这里面的运作机理，目前还没有任何公开信息说明，该公司也未对其做任何说明。
Second, even though there is ample evidence that the first case cured in the United States did result from Remdesivivir, remember that the drug, originally developed in response to the Ebola virus, now acts on the new crown virus, and there is no publicly available information or explanation about how it works.
从医学角度来说，容不得半点的“歪打正着”或“东方不亮西方亮”，对于为何原先用于埃博拉病毒的药物，现在对新冠病毒起作用，还需要有更有说服里的专业佐证才行。
From a medical point of view, there is no room for either "askew" or "east without west," and more convincing professional support is needed to explain why the drugs originally used for Ebola now work on the new crown virus.
。
.
前述医学教授表示，这一药物在美国进行了I期和II期实验，但II期实验失败，如今面对对抗病毒主体的更换，在中国紧急启动III期临床试验，可能是“特事特办”，在疫情紧急的情况下一路绿灯。
The medical professor said the drug had been tested in phases I and II in the United States, but phase II had failed. Now, faced with the replacement of antiviral agents, the emergency launch of phase III clinical trials in China could be a "special case" with a green light for emergency situations.
。
.
不过针对埃博拉和新型冠状病毒，吉利德此前曾表示，在体外和动物模型中，瑞德西韦证实了对非典型性肺炎（SARS）和中东呼吸综合征（MERS）的病毒病原体均有活性。
But for Ebola and the new coronavirus, Geely has previously shown that in vitro and in animal models, Rhetsevir has demonstrated the virulence of viral pathogens in both SARS and the Middle East Respiratory Syndrome (MERS).
后两者也属于冠状病毒，与新型冠状病毒在结构上非常相似。
The latter two coronavirus also belong to the coronavirus, and the new coronavirus is very similar in structure.
。
.
相关推荐换一换        。
I'd like to exchange it.
进入广告。
Access to advertising.
广告被拦截插件误伤啦，1秒后播放。
The ad was mistakenly injured by the plug-in. Played back in a second.
关闭拦截插件恢复正常。
Close the interceptor plug-in and return to normal.
详情点击。
For more information click.
VIP可关闭广告。
VIP can close ads.
为了给腾讯视频用户提供更多优质美剧，应版权方（华纳）要求，好莱坞会员在观看华纳美剧时无法跳过广告（《吸血鬼日记》《破产姐妹》《无耻之徒》等）。
To provide Tencent video users with more high-quality American dramas, Hollywood members, at the request of Warner, were unable to skip ads while watching Warner's shows ("The Vampire Diary," "Broken Sisters," etc.).
我们会为会员用户继续争取免广告权益，请您谅解，谢谢！。
We will continue to strive for free advertising rights for our members. Please forgive me, thank you.
我知道了!。
I see.
意见反馈。
Feedback from Parties.
腾讯视频 v.qq.com         网络链接似乎出现问题，        你可以 刷新  或 使用兼容模式播放 试试    使用PC客户端播放更稳定  立即下载        返回继续播放            或使用最新 QQ浏览器 / Chrome观看    [ 错误码: xx, xxx ] 我要反馈           暂停     下一集  00:00 / 01:01 直播              01:01  弹幕  高清    高清        480P                      标清        270P                        倍速   0.5x 1.0x 1.25x 1.5x 2.0x    倍速播放   在这里                         全屏    到腾讯视频观看此视频      下一个       即将播放  取消                       免费使用 国家中小学网络云平台开通  50% 75% 100%          画中画                VIDg30675tipbq   播放模式html5hd   分辨率800 x 600   视频宽高864 x 486   音量0%   视频协议https   CDNapd-1dc49c4d2f61eac256a2073c5b3310ea.v.smtcdns.com   下载速度      缓冲质量        帧数   错误码    版本号 3.4.40-1.0.141 (2020-2-17 5:39:23 PM)   播放流水 e5a43178a1bf678026639514b64e011e_70901   drm false   本地日志  点击下载 /          点击清除                腾讯视频观看完整版 免费使用 国家中小学网络云平台开通            00:00    免费使用 国家中小学网络云平台开通救治重症，广东医生与“死神”抢夺生命病毒潜伏期越长越顽劣，最长达10年，全球渗透目前仍无特效药“美国神药”能终结中国疫情吗？瑞德西韦的奇幻漂流每5人就有1人感染！钻石公主号隔离期满，约500人今天下船精彩组图湖南省首家医用防护服生产企业正式投产越来越贵的香烟，“瑟瑟发抖”不仅仅是老烟民的钱包？你准备好戒烟了吗？江苏泰州：检测试剂生产忙中国当前最长寿的老人，出生于清朝光绪12年，每天500人看望热点精选健康新知丨过春节只想宅家？懒人运动法，几分钟让身体“动起来”新春送健康丨寒冷天气心脑血管疾病高发，请收好这份护心锦囊健康新知丨探索生命奥秘，人类体温正在悄然变低？新春送健康丨上班族太难了，这5个黄金建议，帮你化解久坐危害 新春送健康丨女性必知50条健康知识，最后一条你可能不知道精品原创较真丨对患者遗体进行病理检验，为什么那么重要？谷雨丨在线心理咨询师：他们找我们哭一场，然后继续开工较真 | 血浆疗法是什么？有用吗？安全吗？一文读懂血浆疗法的前世今生抗疫护士“前线”故事：已经23天没见自己孩子 想回家但不敢回武汉中心医院医护人员感染始末：接触病人推测可能人传人 上报被批造谣相关推荐换一换教育部：国家中小学网络云平台今开通 免费使用救治重症，广东医生与“死神”抢夺生命病毒潜伏期越长越顽劣，最长达10年，全球渗透目前仍无特效药“美国神药”能终结中国疫情吗？瑞德西韦的奇幻漂流每5人就有1人感染！钻石公主号隔离期满，约500人今天下船。
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
关于腾讯 | About Tencent | 服务协议 | 隐私政策 | 开放平台 | 广告服务 | 腾讯招聘 | 腾讯公益 | 客服中心 | 举报中心 | 网站导航Copyright © 1998 - 2020 Tencent. All Rights Reserved腾讯公司 版权所有。
Re Tencent & # 124; About Tent & # 124; Service Agreement & # 124; Privacy Policy & # 124; Open Platform & # 124; Tencent & # 124; Tencent & # 124; Customer Service Center & # 124; Referral Center & # 124; Web Navigator Copyright? 1998-2020 Tencent. All Rights Reserved Tencent.
用户反馈。
User feedback.
视频信息 复制视频页面地址 复制当前时间的页面地址 复制调试信息 3.4.40 (2020-2-17 5:39:23 PM)    。
Video message replication video page address copy current time page address replication debugging information 3.4.40 (2020-2-17 5: 39: 23 PM).
